Evidence map›Paper›PMID 31544211›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020

Impact of the Introduction of Rotavirus Vaccine on Hospital Admissions for Diarrhea Among Children in Kenya: A Controlled Interrupted Time-Series Analysis.

Grieven P Otieno, Christian Bottomley, Sammy Khagayi, Ifedayo Adetifa, Mwanajuma Ngama, Richard Omore, Billy Ogwel, Betty E Owor, Godfrey Bigogo, John B Ochieng and 11 more

Open access · hybridAbstract readMulticenter Study
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Burden ofBMJ global health · 2026
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The Full Impact of Rotavirus Vaccines in Africa Has Yet to Be Realized.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023
    Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 8 institutions in 5 countries.

Grieven P OtienoKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.
Christian BottomleyLondon School of Hygiene and Tropical Medicine, London, United Kingdom.
Sammy KhagayiKEMRI-Centre for Global Health Research, Kisumu, Kenya.
Ifedayo AdetifaKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.
Mwanajuma NgamaKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.
Richard OmoreKEMRI-Centre for Global Health Research, Kisumu, Kenya.
Billy OgwelKEMRI-Centre for Global Health Research, Kisumu, Kenya.
Betty E OworKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.
Godfrey BigogoKEMRI-Centre for Global Health Research, Kisumu, Kenya.
John B OchiengKEMRI-Centre for Global Health Research, Kisumu, Kenya.
Clayton OnyangoCenters for Disease Control and Prevention-Kenya, Nairobi, Kenya.
Jane JumaKEMRI-Centre for Global Health Research, Kisumu, Kenya.
Jason MwendaWorld Health Organization Regional Office for Africa, Brazzaville, Republic of Congo.
Collins TabuMinistry of Health, Nairobi, Kenya.
Jacqueline E TateCenters for Disease Control and Prevention, Emory University, Atlanta, Georgia, USA.
Yaw AddoEmory Global Health Institute, Emory University, Atlanta, Georgia, USA.
Tuck BrittonEmory Global Health Institute, Emory University, Atlanta, Georgia, USA.
Umesh D ParasharCenters for Disease Control and Prevention, Emory University, Atlanta, Georgia, USA.
Robert F BreimanEmory Global Health Institute, Emory University, Atlanta, Georgia, USA.
Jennifer R VeraniCenters for Disease Control and Prevention-Kenya, Nairobi, Kenya.
D James NokesKenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme, Centre for Geographic Medicine Research-Coast, Kilifi, Kenya.
Kenya Medical Research Institute · KEEmory University · USCenters for Disease Control and Prevention · USCenters for Disease Control and Prevention · KELondon School of Hygiene & Tropical Medicine · GBMinistry of Health · KEUniversity of Lagos · NGWorld Health Organization Regional Office for Africa · CG

Funding

Medical Research Council MR/R010161/1Wellcome Trust 102975Wellcome Trust 203077World Health Organization 001
6 · The paper itself

Abstract

backgroundMonovalent rotavirus vaccine, Rotarix (GlaxoSmithKline), was introduced in Kenya in July 2014 and is recommended to infants as oral doses at ages 6 and 10 weeks. A multisite study was established in 2 population-based surveillance sites to evaluate vaccine impact on the incidence of rotavirus-associated hospitalizations (RVHs).

methodsHospital-based surveillance was conducted from January 2010 to June 2017 for acute diarrhea hospitalizations among children aged <5 years in 2 health facilities in Kenya. A controlled interrupted time-series analysis was undertaken to compare RVH pre- and post-vaccine introduction using rotavirus-negative cases as a control series. The change in incidence post-vaccine introduction was estimated from a negative binomial model that adjusted for secular trend, seasonality, and multiple health worker industrial actions (strikes).

resultsBetween January 2010 and June 2017 there were 1513 and 1652 diarrhea hospitalizations in Kilifi and Siaya; among those tested for rotavirus, 28% (315/1142) and 23% (197/877) were positive, respectively. There was a 57% (95% confidence interval [CI], 8-80%) reduction in RVHs observed in the first year post-vaccine introduction in Kilifi and a 59% (95% CI, 20-79%) reduction in Siaya. In the second year, RVHs decreased further at both sites, 80% (95% CI, 46-93%) reduction in Kilifi and 82% reduction in Siaya (95% CI. 61-92%); this reduction was sustained at both sites into the third year.

conclusionsA substantial reduction in RVHs and all-cause diarrhea was observed in 2 demographic surveillance sites in Kenya within 3 years of vaccine introduction.

Indexed as

GastroenteritisRotavirusRotavirus InfectionsRotavirus VaccinesChildChild, PreschoolDiarrheaHospitalizationHospitalsHumansInfantKenyaRotavirus Vaccinescontrolinterrupted time seriesrotavirus vaccinevaccine impact

Identifiers

PMID31544211
PMCPMC7245159
OpenAlexW2976539564

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.